ZIOPHARM Oncology Inc Stock News

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation bene

ISS Acknowledges Ziopharm's Outperformance of its Peer Group During Chairman Scott Tarriff's Tenure

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation bene

Co ntinues to Execute on Strategy to Ensure Strong Long-Term Outlook

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation bene

– First Data from Ongoing Phase 2 Study of Controlled IL-12 in Combination with Cemiplimab Demonstrate Promising Safety Profile in rGBM,  and a Confirmed Partial Response –

– Pharmaceutical Executive with 2 0 + Year s of Experience Across All Phases of Clinical Research Including IND Submission s , Trial Design and Regulatory Filings –

– Special Advisor and Former Chief of Staff for the Bill & Melinda Gates Medical Research Institute Joins as Independent Director –

BOSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q3 2020 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation bene

Urges Shareholders to Sign and Return Ziopharm's GREEN Consent Revocation Card